Targeting CALM2 Inhibits Hepatocellular Carcinoma Growth and Metastasis by Suppressing E2F5-mediated Cell Cycle Progression

Anticancer Res. 2021 Mar;41(3):1315-1325. doi: 10.21873/anticanres.14889.

Abstract

Background/aim: The aim of this study was to reveal the novel roles of calmodulin 2 (CALM2) in hepatocellular carcinoma (HCC) progression.

Materials and methods: The effects of knockdown of CALM2 expression by siRNA were investigated using various experimental approaches in both cellular and molecular levels.

Results: Silencing of CALM2 inhibited HCC cell proliferation and colony formation through induction of apoptosis. At the molecular level, CALM2-specific knockdown led to the common dysregulation of 154 genes in HCC cells. Notably, E2F transcription factor 5 (E2F5), which is functionally associated with migration, invasion and proliferation, was generally down-regulated. These functional associations were confirmed in HCC clinical samples. Reflecting the molecular changes, CALM2 knockdown reduced the migration and invasion abilities of HCC cells and abrogated the potency of tumor formation in vivo.

Conclusion: Targeting CALM2 may be a molecular strategy for both primary HCC treatment and prevention of metastasis or recurrence.

Keywords: CALM2; E2F5; HCC; calcium signaling; cell cycle; therapeutic target.

MeSH terms

  • Apoptosis / drug effects
  • Calmodulin / antagonists & inhibitors
  • Calmodulin / physiology*
  • Carcinoma, Hepatocellular / pathology*
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • E2F5 Transcription Factor / physiology*
  • Humans
  • Liver Neoplasms / pathology*
  • Neoplasm Metastasis
  • Neoplastic Stem Cells / physiology

Substances

  • CALM2 protein, human
  • Calmodulin
  • E2F5 Transcription Factor
  • E2F5 protein, human